SBFM Phase 3 readout: a positive outcome, +7.2%

On March 10, 2026, Sunshine Biopharma Inc. reached its Phase 3 readout. The result was a positive outcome, and the stock moved +7.2% in the window around the event. It had already run -7.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.